Keyword: Bi Jingquan

Bi Jingquan, who headed CFDA for three years, was asked to resign from his current position at the all-powerful State Administration for Market Regulation.

China plans to eliminate major regulatory barriers for foreign drugs, Tessa bought Euchloe for its checkpoint inhibitors, and J&J and Lilly CEOs supported globalization.

China's Food and Drug Administration proposed changes to its foreign drug approval rules in a bid to speed new, innovative meds to market.

Wockhardt was hit with a seventh FDA warning letter, China's FDA chief pledged to speed up approvals of foreign drugs, and an Indian court ruled on patent cases concerning copycats of Herceptin and two on-patent Bayer blockbusters.

CFDA's top official pledged to tackle barriers in drug approval to draw more advanced foreign drugs into the market.